Piperine

Small molecule

HHospital de Mataró

Piperine is one of 19 small molecule programs targeting Dysphagia. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DysphagiaActive, not recruiting

DysphagiaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

30 competitors in Dysphagia

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Approved

5 2

Medrol

Pfizer

Phase 3

2 3

Botox

RRevance Therapeutics, Inc.

Phase 3

1 4

Resotran

Takeda

Phase 2

1 5

Provigil

NNuvo Research GmbH

Phase 2

1 6

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 7

Austedo

Teva

Phase 1

1 8

Nicergoline

HHannover Medical School

Phase 3

1 9

Zofran

Novartis

Preclinical

1 10

Buspar

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dysphagia1 trial

Effect Of Piperine In Patients With Oropharyngeal Dysphagia

Completed·HHospital de Mataró·Phase 1/2·NCT01383694·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Piperine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Piperine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Piperine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospital de Mataró company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: HHospital de Mataró

Piperine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dysphagia1 trial

References

Drug Info

Quick Facts

Related News